Efficacy and safety of albumin-bound paclitaxel, cisplatin and capecitabine in combination with sequential concurrent chemoradiotherapy combined with apatinib and camrelizumab for stage N3M0 nasopharyngeal carcinoma: a prospective, open labeled phase II clinical trial
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms QUINTUPLED trial
- 07 Jun 2022 Results (n=50) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 04 Aug 2020 New trial record